A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis

British Journal of Dermatology

Volumn 175, Issue 6, 2016, Pages 1195-1203

  Takahashi, T ^a   Asano, Y ^a   Nakamura, K ^a   Yamashita, T ^a   Saigusa, R ^a   Ichimura, Y ^a   Toyama, T ^a   Taniguchi, T ^a   Yoshizaki, A ^a   Tamaki, Z ^a   Tada, Y ^a   Sugaya, M ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; ANTIMICROBIAL CATIONIC PEPTIDE; ANTIMICROBIAL PEPTIDE LL-37; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE; FLI1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR FLI 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; FINGER ULCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KERATINOCYTE; LUNG ALVEOLITIS; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAYNAUD PHENOMENON; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; UPREGULATION; VASCULAR DISEASE; YOUNG ADULT; ANIMAL; BLOOD; C57BL MOUSE; DEFICIENCY; ENDOTHELIUM CELL; FEMALE; FIBROSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SCLERODERMA, SYSTEMIC; SKIN; VASCULAR DISEASES;

ADULT; AGED; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CATHELICIDINS; ENDOTHELIAL CELLS; FEMALE; FIBROSIS; HUMANS; INTERFERON-ALPHA; MICE, INBRED C57BL; MIDDLE AGED; PROTO-ONCOGENE PROTEIN C-FLI-1; SCLERODERMA, SYSTEMIC; SKIN; UP-REGULATION; VASCULAR DISEASES;

EID: 84997701192     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14699     Document Type: Article

References (42)

1. Asano Y. Future treatments in systemic sclerosis. J Dermatol 2010; 37:54–70.
2. Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol 2013; 191:4895–901.
3. Yamasaki K, Schauber J, Coda A et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006; 20:2068–80.
4. Kim HJ, Cho DH, Lee KJ et al. LL-37 suppresses sodium nitroprusside-induced apoptosis of systemic sclerosis dermal fibroblasts. Exp Dermatol 2011; 20:843–5.
5. Hizal M, Bruni C, Romano E et al. Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease? Clin Rheumatol 2015; 34:795–8.
6. Spyropoulos DD, Pharr PN, Lavenburg KR et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 2000; 20:5643–52.
7. Takahashi T, Asano Y, Ichimura Y et al. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheumatol 2015; 67:254–65.
8. Asano Y, Czuwara J, Trojanowska M. Transforming growth factor-β regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007; 282:34672–83.
9. Yoshizaki A, Iwata Y, Komura K et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172:1650–63.
10. Ichimura Y, Asano Y, Akamata K et al. Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 2014; 306:331–8.
11. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202–5.
12. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72:1747–55.
13. Noda S, Asano Y, Aozasa N et al. Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis. Arch Dermatol Res 2013; 305:325–31.
14. Takahashi T, Asano Y, Akamata K et al. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis. Mod Rheumatol 2013; 23:884–90.
15. Asano Y, Stawski L, Hant F et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176:1983–98.
16. Akamata K, Asano Y, Aozasa N et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther 2014; 16:R86.
17. Noda S, Asano Y, Akamata K et al. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 2012; 7:e32272.
18. Noda S, Asano Y, Takahashi T et al. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 2013; 52:790–9.
19. Akamata K, Asano Y, Taniguchi T et al. Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. Rheumatology (Oxford) 2015; 54:1308–16.
20. Saigusa R, Asano Y, Taniguchi T et al. A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis. Exp Dermatol 2015; 24:127–32.
21. Noda S, Asano Y, Nishimura S et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 2014; 5:5797.
22. Taniguchi T, Asano Y, Akamata K et al. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated fli-1-haploinsufficient mice. Arthritis Rheumatol 2015; 67:517–26.
23. Asano Y. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis. Int J Biochem Cell Biol 2015; 67:86–91.
24. Elloumi HZ, Holland SM. Complex regulation of human cathelicidin gene expression: novel splice variants and 5ʹUTR negative regulatory element. Mol Immunol 2008; 45:204–17.
25. Termen S, Tollin M, Rodriguez E et al. PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells. Mol Immunol 2008; 45:3947–55.
26. Black CM, Silman AJ, Herrick AI et al. Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42:299–305.
27. Hügle T, Gratzl S, Daikeler T et al. Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced? Ann Rheum Dis 2009; 68:47–50.
28. Pelidou SH, Tsifetaki N, Giannopoulos S et al. Multiple sclerosis associated with systemic sclerosis. Rheumatol Int 2007; 27:771–3.
29. Spadaro A, Sensi F, Barrella M, Francia A. Systemic sclerosis and multiple sclerosis. J Neurol 1999; 246:497–9.
30. Tahara H, Kojima A, Hirokawa T et al. Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C. Intern Med 2007; 46:473–6.
31. Solans R, Bosch JA, Esteban I, Vilardell M. Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004; 22:625–8.
32. Beretta L, Caronni M, Vanoli M, Scorza R. Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders. Br J Dermatol 2002; 147:385–6.
33. Duan H, Fleming J, Pritchard DK et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008; 58:1465–74.
34. Asano Y, Bujor AM, Trojanowska M. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci 2010; 59:153–62.
35. Duncan MR, Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 1987; 79:1318–24.
36. Pammer J, Reinisch C, Birner P et al. Interferon-α prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab Invest 2006; 86:997–1007.
37. Sgonc R, Gruschwitz MS, Dietrich H et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98:785–92.
38. Taniguchi T, Asano Y, Hatano M et al. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. Br J Dermatol 2012; 166:417–21.
39. Koczulla R, von Degenfeld G, Kupatt C et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111:1665–72.
40. Saigusa R, Asano Y, Taniguchi T et al. Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. Proc Natl Acad Sci USA 2015; 112:15136–41.
41. Suzuki K, Murakami T, Kuwahara-Arai K et al. Human anti-microbial cathelicidin peptide LL-37 suppresses the LPS-induced apoptosis of endothelial cells. Int Immunol 2011; 23:185–93.
42. Aden N, Nuttall A, Shiwen X et al. Epithelial cells promote fibroblast activation via IL-1α in systemic sclerosis. J Invest Dermatol 2010; 130:2191–200.